Abstract
Continuation of combined hormonal contraceptive (CHC) therapy is critical for contraceptive success but has previously been evaluated in small patient populations. This is the first evaluation of continuation rates specifically comparing the 91-day extended oral contraceptive (OC) to 28-day cycle formulations.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
